SCHEMBL3283166

SCHEMBL3283166

Cc1cc(/C=C2\C(=O)Nc3ccccc32)c2cccccc1-2

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.76
KDR P35968 3/20 0.60
NPC1 O15118 3/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
CSF1R P07333 2/20 0.60
RET P07949 2/20 0.60
FGFR1 P11362 2/20 0.60
SRC P12931 2/20 0.60
FLT1 P17948 2/20 0.60
FGFR3 P22607 2/20 0.60
MAPK1 P28482 2/20 0.60
FLT4 P35916 2/20 0.60
ALK Q9UM73 2/20 0.60
PLK4 O00444 2/20 0.60
LMNA P02545 2/20 0.60
GMNN O75496 1/20 0.60
USP2 O75604 1/20 0.60
ABL1 P00519 1/20 0.60
PDGFRB P09619 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283170 1.00 FLT3 (0.76) FLT3KDRNPC1MEN1KMT2A
SCHEMBL3283165 1.00 FLT3 (0.76) FLT3KDRNPC1MEN1KMT2A
SCHEMBL3282655 0.87 FLT3 (1.00) FLT3KDRNPC1MEN1KMT2A
SCHEMBL3290777 0.87 FLT3 (1.00) FLT3KDRNPC1MEN1KMT2A
SCHEMBL3282652 0.87 FLT3 (1.00) FLT3KDRNPC1MEN1KMT2A
SCHEMBL5476109 0.83 MEN1 (0.74) FLT3KDRNPC1MEN1KMT2A
SCHEMBL5476114 0.83 MEN1 (0.74) FLT3KDRNPC1MEN1KMT2A
SCHEMBL3285977 0.83 FLT3 (0.68) FLT3KDRNPC1MEN1KMT2A
SCHEMBL3285974 0.83 FLT3 (0.68) FLT3KDRNPC1MEN1KMT2A
SCHEMBL5481714 0.81 MEN1 (0.71) FLT3KDRNPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 US disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 US disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 US disclosed
EP-1918277-A2 Azulene compounds Industrial Technology Research Institute (TW) 2008-05-07 EP disclosed
EP-1918277-A2 Azulene compounds Industrial Technology Research Institute (TW) 2008-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125590-A1 Azulene compounds AZI2, PRMT5, BRCA1 FLT3 796/4885KDR 2548/4885NPC1 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.